Safety and Effectiveness Study Comparing Dabigatran, Rivaroxaban & Apixaban in Non-valvular Atrial Fibrillation Patients Enrolled in the US Department of Defense Military Health System
Phase of Trial: Phase IV
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Dabigatran etexilate (Primary) ; Apixaban; Rivaroxaban
- Indications Atrial fibrillation
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 22 Sep 2017 Status changed from recruiting to completed.
- 18 Aug 2017 Planned End Date changed from 30 Jun 2017 to 29 Sep 2017.
- 18 Aug 2017 Planned primary completion date changed from 30 Jun 2017 to 29 Sep 2017.